RTSN

10.51019.22%
SB

Sabine Bisson

Chief Operations Officer

Ms. Sabine Bisson, Ph.D, is Chief Operating Officer of Response Pharmaceuticals INC. Ms. Bisson is Chief Operations Officer of Retension Pharmaceuticals, Inc. from January 2024. She is a mission-driven, collaborative and dynamic strategic thinker, operational driver and problem solver. She has held key positions in small and growing biotech companies, overseeing development and partnership activities across the R&D lifecycle. With nearly 20 years of strategic and operational leadership, she brings extensive cross-functional experience at the program, portfolio and corporate level. During her tenure at Regeneron Pharmaceuticals, Sabine spent 8 years in the immune/inflammation and cardiometabolic space, playing a key role in the full development cycle of the PCSK9 inhibitor Praluent® (alirocumab) for cardiovascular disease. As head of Regeneron’s Immuno-Oncology portfolio, she drove operational excellence within her department and led the development and partnership activities for multiple assets, including the approval of Libtayo® (cemiplimab) across multiple indications. Subsequently, Sabine established the Program and Portfolio Management function at Cellectis, a cell and gene therapy company and served as the integrated development lead for the company’s preclinical and clinical programs. Most recently, she was VP of Development Leadership at Volastra Therapeutics, advancing the company’s lead small molecule asset and supporting the acquisition of Amgen’s Kif18A inhibitor. Sabine began her academic career in Germany before earning her Ph.D. in Biochemistry and Molecular Biology at the University of Calgary in Canada. She then completed her postdoctoral training as a Howard Hughes Scholar at the University of California, San Francisco.

Positions